ArticleEBioMedicine2026
Epigenetic ageing is accelerated in drug-resistant epilepsy and dynamically modulated during ketogenic diet therapy.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe ketogenic diet (KD) is an established treatment for drug-resistant epilepsy. Beyond seizure reduction, many patients report improved energy, cognition, and well-being. DNA methylation (DNAm)-based epigenetic clocks provide molecular indices of biological ageing and may capture short-term adaptations induced by dietary therapy.
methodsFifty-eight adults with drug-resistant epilepsy completed a 12-week modified KD intervention with blood sampling at baseline, four weeks, and 12 weeks. Whole-blood DNAm was profiled using the Illumina EPIC array. Epigenetic ageing was estimated using cumulative clocks (Horvath, Hannum, Levine) and the rate-based DunedinPACE clock. Longitudinal changes were assessed using linear mixed-effects models. DunedinPACE trajectories were clustered using k-means. Associations with β-hydroxybutyrate, seizure frequency, body weight, and health-related quality of life were assessed using correlations and between-cluster comparisons.
findingsAt baseline, participants showed substantial epigenetic age acceleration on cumulative clocks. Cumulative age acceleration did not change during the intervention. In contrast, DunedinPACE revealed two marked ageing-rate trajectories: an initial increase followed by slowing ("up-down") and an initial slowing followed by rebound ("down-up"). Mean ageing rate did not change at the group level (p = 0.18). However, the "up-down" cluster exhibited significantly greater improvement in quality of life compared with the "down-up" cluster (ΔQOLIE 18.8 versus 4.7; p = 0.007) independent of ketosis, seizure reduction, or weight change.
interpretationDrug-resistant epilepsy is associated with increased cumulative epigenetic ageing. While cumulative age remained stable during modified KD therapy, dynamic ageing-rate patterns were linked to patient-reported benefit, suggesting that rate-based DNAm clocks capture short-term systemic adaptation to metabolic treatment.
fundingThis study was funded by the Dam Foundation, the Norwegian Epilepsy Association's Research Fund, the Novo Nordisk Foundation, and the National Advisory Unit on Rare Disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.